Tanios Bekaii-Saab

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, United States Electronic address
    Crit Rev Oncol Hematol 91:9-34. 2014
  2. pmc CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
    Christina Wu
    The Ohio State University Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Chemother Res Pract 2012:359041. 2012
  3. ncbi request reprint KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents
    Tanios Bekaii-Saab
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University Arthur James Cancer Hospital, Columbus, OH 43210 1240, USA
    Clin Colorectal Cancer 8:135-40. 2009
  4. pmc A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
    Tanios Bekaii-Saab
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    BMC Cancer 6:278. 2006
  5. pmc Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Columbus, OH 43210, USA
    J Clin Oncol 29:2357-63. 2011
  6. pmc A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 15:5895-901. 2009
  7. doi request reprint A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, B407 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 65:863-9. 2010
  8. pmc A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
    Amir Mortazavi
    Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University and the Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Ave, Columbus, OH, 43210, USA
    Invest New Drugs 31:685-95. 2013
  9. doi request reprint A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas
    Marisa E Hill
    Ohio State University Comprehensive Cancer Center, Arthur James Cancer Hospital, Columbus, OH, 43210, USA
    Cancer Chemother Pharmacol 67:511-7. 2011
  10. pmc Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma
    Jeffrey S Rose
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio 43210, USA
    Cancer 118:6243-52. 2012

Detail Information

Publications43

  1. ncbi request reprint Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, United States Electronic address
    Crit Rev Oncol Hematol 91:9-34. 2014
    ..Appropriate administration of chemotherapy/biologic combinations is critical. ..
  2. pmc CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
    Christina Wu
    The Ohio State University Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Chemother Res Pract 2012:359041. 2012
    ..Hereby, we examine preclinical and clinical data that supports the utilization of all three phenotypes in future research applied to clinical practice...
  3. ncbi request reprint KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents
    Tanios Bekaii-Saab
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University Arthur James Cancer Hospital, Columbus, OH 43210 1240, USA
    Clin Colorectal Cancer 8:135-40. 2009
    ..These findings are likely to change the landscape of metastatic CRC treatment by providing an improved patient-tailored approach...
  4. pmc A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
    Tanios Bekaii-Saab
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    BMC Cancer 6:278. 2006
    ..In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers...
  5. pmc Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Columbus, OH 43210, USA
    J Clin Oncol 29:2357-63. 2011
    ..Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy of selumetinib in BC...
  6. pmc A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 15:5895-901. 2009
    ..HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC...
  7. doi request reprint A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies
    Tanios Bekaii-Saab
    The Ohio State University Comprehensive Cancer Center, B407 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 65:863-9. 2010
    ..On the basis of the time-dependency of this upregulation, we performed a phase I dose escalation study of capecitabine and MMC in patients with gastrointestinal malignancies...
  8. pmc A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
    Amir Mortazavi
    Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University and the Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Ave, Columbus, OH, 43210, USA
    Invest New Drugs 31:685-95. 2013
    ..We conducted a phase I trial to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of prolonged triapine infusion followed by FDR-G...
  9. doi request reprint A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas
    Marisa E Hill
    Ohio State University Comprehensive Cancer Center, Arthur James Cancer Hospital, Columbus, OH, 43210, USA
    Cancer Chemother Pharmacol 67:511-7. 2011
    ..Pancreas cancer remains a formidable challenge. We report the first prospective analysis of the 3-drug combination of gemcitabine (G), docetaxel (T) and capecitabine (X) (mGTX) with schedule modification to maximize biomodulation of X...
  10. pmc Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma
    Jeffrey S Rose
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio 43210, USA
    Cancer 118:6243-52. 2012
    ..The prognostic value of KRAS in metastatic disease, specifically according to whether patients have synchronous or metachronous disease at presentation, is less understood...
  11. pmc A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
    Erin M Bertino
    The Ohio State University Wexner Medical Center, Department of Internal Medicine, Division of Medical Oncology, Columbus, OH, USA
    Lung Cancer 79:27-32. 2013
    ..The trial also evaluated the correlation between peripheral blood dihydropyrimidine dehydrogenase (DPD) expression and efficacy/toxicity...
  12. doi request reprint HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib
    Joshua Peck
    The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA
    Oncology 82:175-9. 2012
    ..Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC...
  13. pmc A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Invest New Drugs 30:629-38. 2012
    ....
  14. pmc Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma
    Maryam B Lustberg
    Department of Internal Medicine, Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210 1240, USA
    J Thorac Oncol 5:713-8. 2010
    ....
  15. pmc Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer
    Elaine T Lam
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210 1240, USA
    Cancer Chemother Pharmacol 66:1019-29. 2010
    ..The present study evaluated the safety and tolerability of suramin in combination with docetaxel or gemcitabine in previously chemotherapy-treated patients with advanced non-small cell lung cancer...
  16. ncbi request reprint A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors
    Ludmila K Martin
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH, USA
    Onkologie 36:657-60. 2013
    ....
  17. doi request reprint Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials
    Todd M Bauer
    Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Cancer 119:285-92. 2013
    ..Carbohydrate antigen 19-9 (CA19-9) is a widely used biomarker in pancreatic cancer. There is no consensus on the interpretation of the change in CA19-9 serum levels and its role in the clinical management of patients with pancreatic cancer...
  18. pmc A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer
    Ludmila Katherine Martin
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Int J Radiat Oncol Biol Phys 84:e475-81. 2012
    ....
  19. doi request reprint STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells
    Li Lin
    Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Department of Pediatrics, Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43205, USA
    Biochem Biophys Res Commun 416:246-51. 2011
    ..In summary, our results indicate that STAT3 is a novel therapeutic target in colon cancer stem-like cells and inhibition of STAT3 in cancer stem-like cells may offer a potential treatment for colorectal cancer...
  20. doi request reprint Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
    Allyson J Ocean
    Department of Medicine, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 118:5497-506. 2012
    ....
  21. pmc Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases
    Ludmila Katherine Martin
    Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Clin Colorectal Cancer 11:195-9. 2012
    ..Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y radioembolization...
  22. doi request reprint A phase I study of topotecan and gemcitabine in advanced solid tumors
    Derek S Serna
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    Invest New Drugs 29:1390-4. 2011
    ..Synergism has been demonstrated in vitro when gemcitabine and other topoisomerase I inhibitors have been combined...
  23. doi request reprint Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials
    Nse Ntukidem
    Department of Medicine, The Ohio State University, Columbus, USA
    Cancer Chemother Pharmacol 65:319-24. 2010
    ..One of the most devastating toxicities MMC has been associated with is thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in 4-15% of patients, especially when receiving cumulative doses higher than 60 mg/m(2)...
  24. ncbi request reprint Emerging treatments in recurrent and metastatic colorectal cancer
    Kristen Keon Ciombor
    From the Division of Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    J Natl Compr Canc Netw 11:S18-27. 2013
    ..Optimal drug combinations and treatment sequences have yet to be defined, but an expanding armamentarium of therapies with which to treat CRC offers a promising future. ..
  25. doi request reprint A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
    Edward J Kim
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Cancer 119:2692-700. 2013
    ..The purpose of this study was to evaluate preoperative treatment with full-dose gemcitabine, oxaliplatin, and radiation therapy (RT) in patients with localized pancreatic cancer...
  26. pmc Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer
    Ludmila Katherine Martin
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, M365 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Med Oncol 29:3101-7. 2012
    ..CA19-9 level decrease of >25 % predicts improved survival in advanced disease on chemotherapy...
  27. doi request reprint Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study
    Marlo Blazer
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio 43212, USA
    Oncology 83:135-40. 2012
    ..Beginning in August of 2009, ondansetron was replaced by PALO 0.25 mg (intravenous push)...
  28. pmc A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    The Ohio State University, B401, Starling Loving Hall, 320 W 10th av, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 66:151-8. 2010
    ..A phase I study to determine the maximum tolerated dose (MTD) of bortezomib (B) when combined with weekly paclitaxel in patients with advanced solid tumors...
  29. pmc Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner
    Thomas A Mace
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Cancer Res 73:3007-18. 2013
    ..These results identify a novel role for PSC in driving immune escape in pancreatic cancer and extend the evidence that STAT3 acts as a driver of stromal immunosuppression to enhance its interest as a therapeutic target...
  30. pmc Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy
    Bethany L Mundy-Bosse
    Department of Integrated Biomedical Sciences, The Ohio State University, Columbus, OH, USA
    Cancer Immunol Immunother 60:1269-79. 2011
    ..033). These data provide evidence for a unique relationship between specific cytokines, MDSC subsets, and IFN-α responsiveness in patients with GI malignancies...
  31. ncbi request reprint An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma
    Peyman Haghighat
    Department of Medicine, Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University, Columbus, Ohio 43210 1240, USA
    J Natl Compr Canc Netw 6:895-900. 2008
    ..This article reviews current active chemotherapeutic regimens and explores the role of novel targeted therapies in advanced GGA...
  32. ncbi request reprint Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab
    Shubham Pant
    Division of Hematology and Oncology, Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma
    Cancer 120:1780-6. 2014
    ..The authors evaluated baseline serum albumin (b-alb) as a predictive biomarker in a pooled analysis from 7 prospective clinical trials of gemcitabine-based therapy with or without bevacizumab...
  33. ncbi request reprint The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience
    Ludmila Katherine Martin
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Ann Surg Oncol 21:862-7. 2014
    ..There is no consensus on the added value of radiotherapy (RT). We conducted a retrospective analysis of clinical outcomes in pancreas cancer patients treated with CT or CRT following surgery...
  34. doi request reprint Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series
    Ludmila Katherine Martin
    The Ohio State University James Cancer Hospital, 320 West 10th Avenue, Columbus, OH 43210, USA
    Photomed Laser Surg 30:668-71. 2012
    ..The purpose of this study was to evaluate the role of photodynamic therapy (PDT) in primary tracheal carcinomas...
  35. ncbi request reprint Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin
    Ludmila Katherine Martin
    Department of Internal Medicine, Division of Medical Oncology, Section of Gastrointestinal Oncology, The Ohio State University Medical Center, Columbus Ohio, USA
    J Natl Compr Canc Netw 11:298-307; quiz 307. 2013
    ..This article reviews the existing literature and explores the potential role of oxaliplatin as part of neoadjuvant CRT for rectal cancer...
  36. pmc Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer
    Bhuvaneswari Ramaswamy
    Division of Hematology and Oncology, Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH 43210, USA
    Invest New Drugs 29:347-51. 2011
    ..We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental..
  37. ncbi request reprint Prostate cancer incidence in males with Lynch syndrome
    Sigurdis Haraldsdottir
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA
    Genet Med 16:553-7. 2014
    ..Conclusion:Males with Lynch syndrome had a nearly fivefold increased risk of developing prostate cancer but did not appear to have earlier onset or a more aggressive phenotype.Genet Med 16 7, 553-557. ..
  38. doi request reprint Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo
    Kevin Chu Foy
    Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH 43210, USA
    J Immunol 191:217-27. 2013
    ..Our results show that this novel EGFR B cell epitope has great potential to be used as a vaccine or treatment option for EGFR-expressing cancers...
  39. doi request reprint Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab
    Katherine Van Loon
    From the Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA Division of Medical Oncology, College of Medicine, The Ohio State University Medical Center, Columbus, OH Division of Biomedical Statistics and Informatics, Health Sciences Research Department, The Mayo Clinic, Rochester, MN and Division of Hematology and Oncology, The Mayo Clinic, Jacksonville, FL
    Pancreas 43:343-9. 2014
    ..The objective of this study was to evaluate whether building upon multidrug chemotherapy regimens represents a viable strategy in pancreatic cancer clinical trial design...
  40. pmc Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?
    Ludmila Katherine Martin
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, M365 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA
    Thrombosis 2012:758385. 2012
    ..This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate, rivaroxaban, and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer-related VTE...
  41. pmc Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report
    Brian J So
    The Ohio State University Medical Center, 395 W, 12th Avenue, Columbus, OH 43210, USA
    J Hematol Oncol 1:18. 2008
    ..No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy...
  42. pmc Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells
    Lauren Friedman
    Department of Pediatrics, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, OH 43205, USA
    Anticancer Drugs 20:444-9. 2009
    ....
  43. ncbi request reprint Hepatobiliary cancers. Clinical practice guidelines in oncology
    Al B Benson
    Robert H Luri Comprehensive Cancer Center of Northwestern University
    J Natl Compr Canc Netw 4:728-50. 2006